The US Department of Veterans Affairs has synthesized substituted aminopiperazine compounds reported to be useful for the treatment of bacterial and fungal infections.
During the IDWeek conference held in Boston earlier this month, presentations on Climate Change were spread throughout the program. Some talks were on the direct effects of weather on infectious agents. Others discussed what healthcare workers could do to mitigate the effects of climate change, from antibiotic stewardship to decarbonization of day to day operations.
The co-founders of Zero Candida Ltd. described, in the company’s first PCT filing, their development of a drug-free solution for treating vaginal fungal infections using an intravaginal light-based treatment device (ILTD) that projects light at predefined intervals and intensities to treat infection.
Turbinmicin analogues reported to be useful for the treatment of fungal infections have been described in a recent Wisconsin Alumni Research Foundation (WARF) patent.
Research at Middle Tennessee State University has led to the development of peptoids reported to be useful for the treatment of fungal infections and tuberculosis.
Preclinical research led by the University Hospital Würzburg in Germany shows early promise for chimeric antigen receptor (CAR) T-cell therapies to treat invasive pulmonary aspergillosis, a serious fungal infection with limited current treatment options.
LONDON – Pulmocide Ltd. has closed a $92 million oversubscribed series C, providing the means to take its inhaled antifungal drug, PC-945, through a global phase III registration study in invasive pulmonary aspergillosis.